GlaxoSmithKline (GSK) Gets a Hold from UBS
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...
GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...
A small team of Australian scientists won a rare drug approval – and upended the pharma system
Hundreds of thousands of doses of moxidectin – which treats a disease caused by a parasitic worm – are being given to ...
Investing6h
GSK lifts long-term sales outlook on strong Specialty Medicines growth
GSK’s global performance showed strength across key markets. Sales in the United States reached £16.4 billion, up 6% at ...
GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook — 2nd Update
GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.
GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views — Update
GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The British pharmaceutical giant said Wednesday that the 2.0 billion-pound ...
GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook
The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...
FTSE 100 LIVE: Stocks mixed as Trump's trade war pushes gold prices to record high
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
GSK lifts long-term sales targets on new drug pipeline
Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline.It ...
bovnews19h
GSK’s Unexpected Plunge: What’s Next?
On Monday, GSK plc (GSK) stock saw a decline, ending the day at $34.9 which represents a decrease of $-0.37 or -1.05% from the prior close of $35.27. The stock opened at $34.87 and touched a low of ...
EconoTimes1h
GSK Raises 2031 Sales Forecast to £40B Amid Strong Specialty Medicine Growth
GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.
GSK shares rise over 5% after Q4 results
GlaxoSmithKline plc (NYSE: NYSE:GSK) shares gained 5.65% after the pharmaceutical giant reported fourth quarter revenue that beat analyst estimates, despite earnings falling short of expectations.